Accumulation of 8-hydroxy-2′-deoxyguanosine adducts in HBx recombinant HepG2 cells and HBx transgenic mice

Digestion

Volumn 70, Issue 2, 2004, Pages 117-126

  Gehrke, Ralph ^a   Brauchle, Maria A ^a   Reifenberg, Kurt ^b   Hildt, Eberhard ^c   Gruetzner, Uwe ^a   Schmitz, Volker ^e   Schlicht, Hans Jürgen ^d   Hofschneider, Peter Hans ^a   Caselmann, Wolfgang H ^e,f   Rabe, Christian ^e  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

^d UNIVERSITY OF ULM   (Germany)

^e UNIVERSITY OF BONN   (Germany)

^f Bayerisches Staatsministerium F U   (Germany)

Author keywords

Carcinoma; DNA adducts; HBx; Hepatitis B virus; Hepatocellular; Reactive oxygen species; Trans activators metabolism

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ACETYLCYSTEINE; DNA; GENOMIC DNA; REACTIVE OXYGEN METABOLITE; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; CELL REGENERATION; CELL STRAIN; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA ADDUCT; ELECTROCHEMICAL ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INCUBATION TIME; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TRANSACTIVATION; TRANSGENIC MOUSE;

ACETYLCYSTEINE; ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DEOXYGUANOSINE; DNA ADDUCTS; DNA, RECOMBINANT; HUMANS; LIVER; LIVER NEOPLASMS; MICE; MICE, TRANSGENIC; TRANS-ACTIVATORS;

EID: 5644276313     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080930     Document Type: Article

References (55)

1. Beasley RP, Hwang LY, Lin CC, Chien CS: Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22 707 men in Taiwan. Lancet 1981;ii:1129-1133.
2. Caselmann WH: Trans-activation of cellular genes by hepatitis B virus proteins: A possible mechanism of hepatocarcinogenesis. Adv Virus Res 1996;47:253-302.
3. Rabe C, Caselmann WH: Interaction of Hepatitis B virus with cellular processes in liver carcinogenesis. Crit Rev Clin Lab Sci 2000;37:407-429.
4. Seifer M, Hohne M, Schaefer S, Gerlich WH: In vitro tumorigenicity of hepatitis B virus DNA and HBx protein. J Hepatol 1991;13(suppl 4):S61-S65.
5. Seifer M, Gerlich WH: Increased growth of permanent mouse fibroblasts in soft agar after transfection with hepatitis B virus DNA. Arch Virol 1992;126:119-128.
6. Schaefer S, Seifer M, Grimmsmann T, Fink L, Wenderhold S, Hohne MW, Gerlich WH: Properties of tumour suppressor p53 in murine hepatocyte lines transformed by hepatitis B virus X protein. J Gen Virol 1998;79:767-777.
7. Shirakata Y, Kawada M, Fujiki Y, Sano H, Oda M, Yaginuma K, Kobayashi M, Koike K: The X gene of hepatitis B virus induced growth stimulation and tumorigenic transformation of mouse NIH3T3 cells. Jpn J Cancer Res 1989;80:617-621.
8. Balsano C, Billet O, Bennoun M, Cavard C, Zider A, Grimber G, Natoli G, Briand P, Levrero M: Hepatitis B virus X gene product acts as a transactivator in vivo. J Hepatol 1994;21:103-109.
9. Kim CM, Koike K, Saito I, Miyamura T, Jay G: HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991;351:317-320.
10. Yu DY, Moon HB, Son JK, Jeong S, Yu SL, Yoon H, Han YM, Lee CS, Park JS, Lee CH, Hyun BH, Murakami S, Lee KK: Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. J Hepatol 1999;31:123-132.
11. Lee TH, Finegold MJ, Shen RF, DeMayo JL, Woo SL, Butel JS: Hepatitis B virus transactivator X protein is not tumorigenic in transgenic mice. J Virol 1990;64:5939-5947.
12. Reifenberg K, Lohler J, Pudollek HP, Schmitteckert E, Spindler G, Kock J, Schlicht HJ: Long-term expression of the hepatitis B virus core-e- and X-proteins does not cause pathologic changes in transgenic mice. J Hepatol 1997;26:119-130.
13. Rabe C, Cheng B, Caselmann WH: Molecular mechanisms of hepatitis B virus-associated liver cancer. Dig Dis 2001;19:279-287.
14. Madden CR, Finegold MJ, Slagle BL: Expression of hepatitis B virus X protein does not alter the accumulation of spontaneous mutations in transgenic mice. J Virol 2000;74:5266-5272.
15. Madden CR, Finegold MJ, Slagle BL: Hepatitis B virus X protein acts as a tumor promoter in development of diethylnitrosamine-induced preneoplastic lesions. J Virol 2001;75:3851-3858.
16. Sohn S, Jaitovitch-Groisman I, Benlimame N, Galipeau J, Batist G, Alaoui-Jamali MA: Retroviral expression of the hepatitis B virus x gene promotes liver cell susceptibility to carcinogen-induced site specific mutagenesis. Mutat Res 2000;460:17-28.
17. Jia L, Wang XW, Harris CC: Hepatitis B virus X protein inhibits nucleotide excision repair. Int J Cancer 1999;80:875-879.
18. Prost S, Ford JM, Taylor C, Doig J, Harrison DJ: Hepatitis B x protein inhibits p53-dependent DNA repair in primary mouse hepatocytes. J Biol Chem 1998;273:33327-33332.
19. Groisman IJ, Koshy R, Henkler F, Groopman JD, Alaoui-Jamali MA: Downregulation of DNA excision repair by the hepatitis B virus-x protein occurs in p53-proficient and p53-deficient cells. Carcinogenesis 1999;20:479-483.
20. Ames BN: Endogenous oxidative DNA damage, aging, and cancer. Free Radic Res Commun 1989;7:121-128.
21. Sarasin A, Bounacer A, Lepage F, Schlumberger M, Suarez HG: Mechanisms of mutagenesis in mammalian cells. Application to human thyroid tumours. C R Acad Sci III 1999;322:143-149.
22. Duarte V, Muller JG, Burrows CJ: Insertion of dGMP and dAMP during in vitro DNA synthesis opposite an oxidized form of 7,8-dihydro-8-oxoguanine. Nucl Acids Res 1999;27:496-502.
23. Floyd RA, Watson JJ, Wong PK, Altmiller DH, Rickard RC: Hydroxyl free radical adduct of deoxyguanosine: Sensitive detection and mechanisms of formation. Free Radic Res Commun 1986;1:163-172.
24. Schwarz KB, Kew M, Klein A, Abrams RA, Sitzmann J, Jones L, Sharma S, Britton RS, Di Bisceglie AM, Groopman J: Increased hepatic oxidative DNA damage in patients with hepatocellular carcinoma. Dig Dis Sci 2001;46:2173-2178.
25. Jüngst C, Cheng B, Gehrke R, Schmitz V, Nischalke HD, Ramakers J, Schramel P, Schirmacher P, Sauerbruch T, Caselmann WH: Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma. Hepatology 2004;39:1663-1672.
26. Caselmann WH, Meyer M, Kekule AS, Lauer U, Hofschneider PH, Koshy R: A trans-activator function is generated by integration of hepatitis B virus preS/S sequences in human hepatocellular carcinoma DNA. Proc Natl Acad Sci USA 1990;87:2970-2974.
27. Reifenberg K, Wilts H, Lohler J, Nusser P, Hanano R, Guidotti LG, Chisari FV, Schlicht HJ: The hepatitis B virus X protein transactivates viral core gene expression in vivo. J Virol 1999;73:10399-10405.
28. Hildt E, Urban S, Lauer U, Hofschneider PH, Kékulé AS: ER-localization and functional expression of the HBV transactivator MHBst. Oncogene 1993;8:3359-3367.
29. Hildt E, Munz B, Saher G, Reifenberg K, Hofschneider PH: The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/ Erk2 signaling in transgenic mice. EMBO J 2002;21:525-535.
30. Chisari FV, Pinkert CA, Milich DR, Filippi P, McLachlan A, Palmiter RD, Brinster RL: A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 1985;230:1157-1160.
31. Lauer U, Weiss L, Hofschneider PH, Kékulé AS: The hepatitis B virus pre-S/S(t) transactivator is generated by 3) truncations within a defined region of the S gene. J Virol 1992;66:5284-5289.
32. de Wet JR, Wood KV, DeLuca M, Helinski DR, Subramani S: Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol 1987;7:725-737.
33. Sanes JR, Rubenstein JL, Nicolas JF: Use of a recombinant retrovirus to study post-implantation cell lineage in mouse embryos. EMBO J 1986;5:3133-3142.
34. Gupta RC: Nonrandom binding of the carcinogen N-hydroxy-2- acetylaminofluorene to repetitive sequences of rat liver DNA in vivo. Proc Natl Acad Sci USA 1984;81:6943-6947.
35. Kasai H, Nishimura S: Hydroxylation of deoxyguanosine at the C-8 position by ascorbic acid and other reducing agents. Nucl Acids Res 1984;12:2137-2145.
36. Fraga CG, Shigenaga MK, Park JW, Degan P, Ames BN: Oxidative damage to DNA during aging: 8-Hydroxy-2)-deoxyguanosine in rat organ DNA and urine. Proc Natl Acad Sci USA 1990;87:4533-4537.
37. Shigenaga MK, Aboujaoude EN, Chen Q, Ames BN: Assays of oxidative DNA damage biomarkers 8-oxo-2)-deoxyguanosine and 8-oxoguanine in nuclear DNA and biological fluids by high-performance liquid chromatography with electrochemical detection. Methods Enzymol 1994;234:16-33.
38. Harris G, Bashir S, Winyard PG: 7,8-Dihydro-8-oxo-2′-deoxyguanosine present in DNA is not simply an artefact of isolation. Carcinogenesis 1994;15:411-413.
39. Sirma H, Weil R, Rosmorduc O, Urban S, Israel A, Kremsdorf D, Brechot C: Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome. Oncogene 1998;16:2051-2063.
40. Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, Pinkert CA, Brinster RL, Palmiter RD: Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989;59:1145-1156.
41. Liu RH, Jacob JR, Hotchkiss JH, Cote PJ, Gerin JL, Tennant BC: Woodchuck hepatitis virus surface antigen induces nitric oxide synthesis in hepatocytes: possible role in hepatocarcinogenesis. Carcinogenesis 1994;15:2875-2877.
42. Izzotti A, Scatolini L, Lewtas J, Walsh D, De Flora S: Enhanced levels of DNA adducts in the liver of woodchucks infected with hepatitis virus. Chem Biol Interact 1995;97:273-285.
43. Meyer M, Caselmann WH, Schluter V, Schreck R, Hofschneider PH, Baeuerle PA: Hepatitis B virus transactivator MHBst: activation of NFkappa B, selective inhibition by antioxidants and integral membrane localization. EMBO J 1992;11:2991-3001.
44. Waris G, Huh KW, Siddiqui A: Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-kappaB via oxidative stress. Mol Cell Biol 2001;21:7721-7730.
45. Becker SA, Lee TH, Butel JS, Slagle BL: Hepatitis B virus X protein interferes with cellular DNA repair. J Virol 1998;72:266-272.
46. Lee TH, Elledge SJ, Butel JS: Hepatitis B virus X protein interacts with a probable cellular DNA repair protein. J Virol 1995;69:1107-1114.
47. Gottlob K, Pagano S, Levrero M, Graessmann A: Hepatitis B virus X protein transcription activation domains are neither required nor sufficient for cell transformation. Cancer Res 1998;58:3566-3570.
48. Sitterlin D, Lee TH, Prigent S, Tiollais P, Butel JS, Transy C: Interaction of the UV-damaged DNA-binding protein with hepatitis B virus X protein is conserved among mammalian hepadnaviruses and restricted to transactivation-proficient X-insertion mutants. J Virol 1997;71:6194-6199.
49. Feitelson MA, Zhu M, Duan LX, London WT: Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 1993;8:1109-1117.
50. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC: Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 1994;91:2230-2234.
51. Truant R, Antunovic J, Greenblatt J, Prives C, Cromlish JA: Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J Virol 1995;69:1851-1859.
52. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ Jr: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;71:587-597.
53. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-6311.
54. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992;89:7491-7495.
55. Nakae D, Kobayashi Y, Akai H, Andoh N, Satoh H, Ohashi K, Tsutsumi M, Konishi Y: Involvement of 8-hydroxyguanine formation in the initiation of rat liver carcinogenesis by low dose levels of N-nitrosodiethylamine. Cancer Res 1997;57:1281-1287.